• He has been working in the field of bone marrow transplantation for hematological malignancies for the last 25 years and is one of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders. (labiotech.eu)
  • His main contributions and scientific interests are hematopoietic stem cell transplantation, hematological malignancies, cord blood biology and, transplantation, and adoptive cell-mediated immunotherapy including NK cell biology. (labiotech.eu)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • The indications for bone marrow transplantation are increasing from hematological malignancies to more recently solid tumours and numerous autoimmune conditions. (telixpharma.com)
  • Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. (stembook.org)
  • Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. (stembook.org)
  • Although the initial reports showed dismal prognosis, recent data suggest that an increased number of patients with solid and hematological malignancies benefit from intensive care support, with dramatically decreased mortality rates. (springeropen.com)
  • NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (sagepub.com)
  • T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
  • However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Over the last few decades, the treatment of hematological malignancies has gained tremendous headway, but these diseases still have high morbidity and mortality [ 1 - 3 ]. (hindawi.com)
  • Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
  • In recent years, with the increased understanding of the molecular genetic basis of these malignancies, immune-targeted therapy has become a new possibility for the treatment of hematological malignancies. (hindawi.com)
  • It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
  • In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
  • Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure, and is usually conducted to consolidate remission of haematological malignancies. (biomedcentral.com)
  • During the past three decades, major improvements have been made in the treatment and cure of certain hematological malignancies, as well as solid tumors in young patients. (dsjuog.com)
  • Spectrum of Hematological Malignancies, Clonal Evolution and Outcomes in 144 Mayo Clinic Patients with Germline Predisposition Syndromes. (cdc.gov)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • In addition to complications seen from exposure to chemotherapy and radiation, patients undergoing allogeneic transplantation can experience unique late effects secondary to graft versus host disease (GVHD) and autoimmunity. (medscape.com)
  • Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. (biomedcentral.com)
  • Developing assets with potential reduced toxicity compared with chemotherapy. (telixpharma.com)
  • Neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. (medicines.org.uk)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Purpose: To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). (the-medical-dictionary.com)
  • Gonadal toxicity after combination chemotherapy for Hodgkin's disease. (dsjuog.com)
  • For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, including bone marrow transplant patients. (medeasy.health)
  • Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. (cdc.gov)
  • Likewise, many children are now surviving hematopoietic stem-cell transplantation (HSCT) (see related histology slide below) and require structured long-term follow-up care. (medscape.com)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • TLX66 ( 90 Y-besilesomab), is an investigational asset granted orphan drug designation (ODD) status in Europe and the United States for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT), a broad clinical indication. (telixpharma.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • There is a concern that labile plasma iron (LPI), the redox-active form of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. (karger.com)
  • According to Nicholas J. Short, MD, one of the lead investigators of this study, the combination was shown to achieve high response rates and reduce the need for allogeneic hematopoietic stem cell transplantation (HSCT) at first remission in patients with recently diagnosed Ph+ acute ALL. (geneonline.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Several studies show that malnutrition is an independent negative prognostic factor for the survival of children and adults affected by malignant haematological disease and treated by allo-HSCT [ 5 - 8 ]. (biomedcentral.com)
  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (sagepub.com)
  • Ten documented cases of disseminated bone metastasis due to malignancy were evaluated to assess the efficacy of hemibody radiation for pain control. (jortho.org)
  • Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. (kb.se)
  • In cases where there is a myelo-ablative-conditioning regimen, drug-induced toxicities, immunosuppression-induced infections and acute graft-versus-host disease (GVHD) are responsible for 15-25% of early mortalities (D100 mortality) [ 1 ]. (biomedcentral.com)
  • Early and late hematologic toxicity following CD19 CAR-T cells. (shebaonline.org)
  • Thalidomide is active in MM 3 - 7 and produces little hematologic toxicity, indicating that it may be preferred for use as induction therapy. (haematologica.org)
  • Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. (stembook.org)
  • Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. (stembook.org)
  • A t the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, Louisiana, ASH Secretary Cynthia E. Dunbar, MD, explained that the focus of this meeting was more on the long-term impact of both novel targeted therapies and cell and gene therapy on patients, including financial toxicity , patient-reported outcomes and quality of life. (geneonline.com)
  • Secondary endpoints will compare EN and PN with regards to the main haematological, infectious and nutritional outcomes. (biomedcentral.com)
  • Shwachman-Diamond syndrome (SDS), or Shwachman-Bodian-Diamond syndrome, is a rare congenital disorder characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, skeletal and cardiac abnormalities and short stature. (wikipedia.org)
  • 05). Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before transplant. (slideshare.net)
  • Moreover, none of the patients with an EF less than 50% developed cardiac toxicity. (slideshare.net)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients [33]. (slideshare.net)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
  • Gastrointestinal toxicities were the most frequent (97.1%) and all patients received antineoplastic/chemotherapeutic and antiemetic treatment. (bvsalud.org)
  • Indeed, the hematological benefit during eculizumab treatment for PNH is very heterogeneous among patients, and different response categories can be identified. (frontiersin.org)
  • Different factors contribute to residual anemia during eculizumab treatment: underlying bone marrow dysfunction, residual intravascular hemolysis and the emergence of C3-mediated extravascular hemolysis. (frontiersin.org)
  • Indeed, we envision a new scenario of therapeutic complement inhibition, where proximal inhibitors (either anti-C3, anti-FD or anti-FB) may prove effective for the treatment of PNH, either in monotherapy or in combination with anti-C5 agents, eventually leading to drastic improvement of hematological response. (frontiersin.org)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
  • EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (biomedcentral.com)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
  • Sequential hepatic and bone marrow transplantation should be considered as a suitable treatment for most severe cases of EPP with hepatic involvement. (biomedcentral.com)
  • Treatment of patients with B-cell chronic lymphocytic leukaemia (CLL) with sufficient bone marrow reserves. (medscape.co.uk)
  • If there is no response after two treatment cycles and the patient shows no or little haematological toxicity, a careful dose adjustment towards higher doses in subsequent cycles could be considered. (medscape.co.uk)
  • Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. (kb.se)
  • Both transplantation physicians and ophthalmologists should be knowledgeable about nonGVHD ocular complications and provide comprehensive collaborative team care. (kb.se)
  • Four recipients (50%) required dialysis for tubular injury and calcineurin inhibitor toxicity. (ersjournals.com)
  • Dr. Nagler established the first public cord blood bank in Israel and performed the first cord blood transplants from related and unrelated donors in genetic and malignant hematological diseases in Israel. (labiotech.eu)
  • Bone marrow is typically hypocellular, with maturation arrest in the myeloid lineages that give rise to neutrophils, macrophages, platelets and red blood cells. (wikipedia.org)
  • Conditions associated with bone marrow failure such as aplastic anemia with hypocellular marrow, typical bone marrow findings of MDS are a hypercellular marrow for a persons age, dysplasia in 1 to 3 lineages manifested by pseudo Pelger-Huet nuclei, hypogranular neutrophils, micro megakaryocytes, and/or ringed sideroblasts, glass Siri glass, and increased myeloblasts in a subset of patients. (standardofcare.com)
  • The prevalence production, lytic lesions and increased of leptomeningeal infiltration in breast can- plasma cells in the bone marrow [ 1 ]. (who.int)
  • We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. (nature.com)
  • In a study from the United States, long-term survivors of pediatric bone marrow transplantation followed in the Bone Marrow Transplant Survivors Study were compared with survivors of childhood cancer treated without bone marrow transplant from the Childhood Cancer Survivor Study. (medscape.com)
  • A cancer patient may present to the orthopaedic surgeon for disabling bone pain, pathological fracture and/or neurological deficit due to spinal cord or nerve root compression. (jortho.org)
  • Bone pain due to skeletal metastasis causes significant morbidity among cancer patients and is equally difficult to treat for an orthopaedic surgeon .Many a times multiple bones are affected simultaneously. (jortho.org)
  • It is used both by hematopoietic researchers and clinical labs to assess the potency of transplantation units of cord blood (CB) and hematopoietic cellular therapy products. (stemcell.com)
  • The American Society of Parenteral and Enteral Nutrition (ASPEN) and the French-speaking society of clinical nutrition and metabolism (SFNEP) recommend nutritional support during haematopoietic transplantation for patients who are malnourished or have decreased intake or decreased intestinal absorption over a prolonged period (grade B) [ 11 , 12 ]. (biomedcentral.com)
  • Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. (cdc.gov)
  • TLX66-CDx ( 99m Tc-besilesomab) is approved and marketed as Scintimun® by Telix's license partner in approximately 30 countries for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. (telixpharma.com)
  • No significant gastrointestinal ,hematological or pulmonary toxicity was noted .The quality of life was significantly improved. (jortho.org)
  • High-dose chemoradiotherapy is the major cause of organ toxicity. (slideshare.net)
  • Arnon Nagler is director of the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, Tel-Hashomer, Israel and Professor of Medicine at The Tel Aviv University, Tel-Aviv, Israel . (labiotech.eu)
  • NOD-SCID-Gamma (NSG) mice) and measuring the presence of human blood cells in the blood or bone marrow (BM) after extended periods of engraftment, e.g., 20 weeks or longer. (stemcell.com)
  • Footnotes *Testing of whole blood lead level is the most sensitive and specific means in assessing lead toxicity. (aetna.com)
  • Biol Blood Marrow Transplant. (stembook.org)
  • Complete normalization of hemoglobin (complete and major hematological response), is seen in no more than one third of patients, while the remaining continue to experience some degree of anemia (good and partial hematological responses), in some cases requiring regular red blood cell transfusions (minor hematological response). (frontiersin.org)
  • Biology of Blood and Marrow Transplantation. (kb.se)
  • C) 2018 American Society for Blood and Marrow Transplantation. (kb.se)
  • The endothelial activation and stress index (EASIX) score has been reported to predict overall survival (OS) in hematological cancers. (biomedcentral.com)
  • Recent advances in small bowel transplantation and nontransplant surgical techniques now offer hope of sustained survival in the future without parenteral nutrition. (optumhealtheducation.com)
  • Journal of Stem Cell Research and Transplantation is an international, open access, peer reviewed, scholarly journal committed to publish articles in diversified fields of transplantations and applications of stem cell research. (slideshare.net)
  • The Journal of Stem Cell Research and Transplantation publishes latest scientific information, and is generously accessible across the world through internet to go halves the innovations of the researchers for intellectual advancement in this field. (slideshare.net)